Influence of indacaterol on daily physical activity in patients with untreated chronic obstructive pulmonary disease

Yu Nishijima1,*
Seigo Minami1,*
Suguru Yamamoto1
Yoshitaka Ogata1
Taro Koba1,2
Shinji Futami1
Kiyoshi Komuta1

1Department of Respiratory Medicine, Osaka Police Hospital, Tennoji-ku, Osaka, Japan; 2Department of Internal Medicine, National Hospital Organization, Kinki-Chuo Chest Medical Center, Kita-ku, Sakai, Osaka, Japan
*These authors contributed equally to this work

Introduction
Chronic obstructive pulmonary disease (COPD) is caused by a chronic inflammatory process of the airways, due mainly to excessive cigarette smoking. Mortality in COPD is increasing and is predicted to be the third highest cause of death by 2020.1

Exercise capacity evaluated by the peak oxygen uptake2 and 6-minute walk distance3 predicts survival in patients with COPD. Physical activity in daily life is highly correlated with functional exercise capacity.4 Patients with COPD are more inactive in daily life than healthy subjects.4,5 Monitoring of physical activity may be the strongest predictor of all-cause mortality in patients with COPD.6

Pharmacologic therapy is necessary for reducing symptoms and frequency of exacerbation due to COPD, and improving health status and exercise tolerance.7 The inhaled bronchodilator is currently a main player in the pharmacologic management of COPD. There are two types of inhaled long-acting bronchodilators that are recommended for

Background: Indacaterol, a once-daily, long-acting β2-agonist, may improve not only respiratory function, dyspnea symptoms, and quality of life, but also physical activity for patients with chronic obstructive pulmonary disease (COPD). This study aimed to evaluate the effect of 12-week indacaterol therapy on daytime physical activity in patients with untreated COPD.

Methods: The subjects were stable and untreated COPD outpatients with a percent predicted forced expiratory volume in 1 second (%FEV1) below 80%. Baseline assessments included clinical assessment, respiratory function testing, arterial blood gas analysis, the COPD assessment test (CAT™), and the Medical Outcomes Study 36-Item Short-Form Health Survey, Japanese version 2 (SF-36v2). Patients underwent monitoring by uniaxial accelerometer before and after 12 weeks once-daily inhalation of indacaterol 150 µg/day.

Results: Eighteen patients were evaluable. Patient characteristics included a mean age of 74.2 years, and three patients were current smokers. Indacaterol improved mean (% standard deviation [SD]) %FEV1, from 55.2% (±17.9%) to 61.0% (±17.3%) (P=0.003), CAT scores from 16.4 (±10.2) points to 12.4 (±8.2) points (P=0.04), some scales of the SF-36v2 (physical component summary, 41.6±9.7 points to 45.1±7.9 points, P=0.03), and number of daily steps (3,311.5±2,103.3 steps/day to 3,841.8±2,096.8 steps/day, P=0.02), but did not affect daily energy expenditure (85.0±77.2 kcal change to 90.9±56.8 kcal, P=0.29) or exercise duration of an intensity of level 1 or more (36.4±23.9 minutes increase to 40.8±21.6 minutes, P=0.12).

Conclusion: Twelve weeks of indacaterol improved respiratory function and quality of life, but did not significantly affect physical activity in patients with moderate-to-severe COPD.

Keywords: indacaterol, long-acting β2-agonist, chronic obstructive pulmonary disease, physical activity, uniaxial accelerometer
long-term maintenance therapy in patients with moderate-to-
severe COPD: long-acting muscarinic antagonists (LAMA) and
long-acting β₂-agonists (LABA). Indacaterol (Onbreze®
inhalation powder; Novartis International AG, Basel, Swit-
zerland), a once-daily LABA, maintained significant improve-
ment at 12 weeks in forced expiratory volume in one second
(FEV₁) assessed by pulmonary function tests, dyspnea symp-
toms, and quality of life (QOL) in patients with moderate-to-
severe COPD, when compared with placebo, salmeterol, and tiotropium. Recent studies indicated that 2–3 weeks of
indacaterol reduced lung hyperinflation and then improved
exercise endurance. Additionally, 3–4 weeks of indacaterol
also improved daily physical activity. This study aimed to
evaluate the effect of 12-week indacaterol therapy on daily
daytime physical activity in untreated patients with COPD.

Materials and methods

Subjects
Patients were recruited from the outpatient clinic in the
Department of Respiratory Medicine at Osaka Police Hospital.
The inclusion criteria were: 1) 40 years of age or older; 2) a
history of smoking or excessive environmental tobacco smoke;
3) clinically stable COPD according to the Global Initiative
on Obstructive Lung Disease (GOLD) guidelines; 4) a pred-
dicted FEV₁ (%FEV₁) < 80%; 5) no treatment with LABA or
LAMA for more than 4 weeks before enrollment; 6) ability
to walk independently or with a cane; 7) sufficient cognitive
function to follow instructions for using the accelerometer; and
8) written informed consent. The exclusion criteria were: 1)
pregnancy, lactation, suspicion of being pregnant; 2) an exac-
erbation within 1 month before enrollment; 3) other signifi-
cant respiratory diseases or medical problems that precluded
ambulatory activities at home; 4) clinically severe bronchial
asthma; 5) patient undergoing pulmonary rehabilitation; or 6)
a history of hypersensitivity reaction against any LABA.

Experimental design
This was an open-label clinical trial with no randomiza-
tion and no placebo group. To record physical activity,
the patients carried a uniaxial accelerometer, Lifecorder®
Ex 4-second version (Suzuken Corporation, Nagoya, Japan), which analyzed the movement intensity level every 4
seconds on a scale of 0.5 (minimal intensity of movement) to
9 (maximal intensity of movement) on the basis of the magni-
tude and frequency of accelerations. The activity intensity level
measured by Lifecorder Ex is highly related with metabolic
equivalents (METs). Unlike other studies that used Lifecorder
Ex, we purposely did not convert our raw data of activity intensity level into METs. This device was fixed to patient belts or
waistbands for more than 1 week before and 12 weeks after
indacaterol therapy. Patients inhaled indacaterol 150 μg/day
once daily during 12 weeks of the treatment. Thereafter, during
the post-treatment accelerometer monitoring period, patients
continued indacaterol inhalation. Patients were instructed by
nurses on how to correctly use the inhalator device (Breezhaler®
device; Novartis International AG) before indacaterol therapy,
and by physicians on how to set up the device every day from
9 am until 5 pm, before each monitoring period. After each
monitoring period, the patients returned the accelerometers to
the investigators. Thereafter, the stored data were uploaded
to a computer for analysis. Monitoring time was based on the
study by Sugino et al which used a triaxial accelerometer,
Actimeter®, for 7 hours from 10 am to 5 pm in patients with
COPD and concluded that the data from at least three non-rainy
weekdays were reliable. Monitoring data on rainy days, on
hospital visit days, and outside of defined hours, before 9 am or
after 5 pm, and in patients who had insufficient accelerometer
data (less than 3 days) were excluded from analysis.

Before and after indacaterol therapy, all patients under-
went spirometry, assessment of the modified Medical
Research Council (mMRC) dyspnea scale score, the
Japanese version of the COPD assessment test (CAT™), and the
Medical Outcomes Study 36-Item Short-Form Health Survey
Japanese version 2 (SF-36v2). Spirometry was
assessed by an autospirometer (Autospirometer System 7;
Minato Medical Science, Osaka, Japan) according to the
American Thoracic Society guidelines. Before indacaterol
therapy, all patients also received arterial blood gas analysis.
Arterial blood samples from the radial artery under breathing
room air were immediately measured by a blood gas analyzer
(RAPIDPoint® 405 Arterial Blood Gas Analyzer; Siemens
Healthcare Diagnostics Inc, Tarrytown, NY, USA).

The primary outcome was duration of light or more exer-
cise, defined as exercise with an intensity of level 1 or more
monitored by Lifecorder. The secondary outcomes were QOL
questionnaire results and respiratory function. Based on the
previous studies by Pitta et al and Hataji et al the physical
activity time with an intensity of ≥ level 1 was estimated
to increase from 144 minutes (30% of all monitoring dura-
tion in a day, 8 hours) to 201 minutes (42%). For a standard
deviation of 72 minutes (15%), with a one-sided alpha of 5%
and a power of 90%, we estimated that 15 evaluable subjects
would be needed. Given the possibility of incomplete data
in some patients, we estimated that 22 subjects would be
needed for this study.

The ethics committee of the Osaka Police Hospital
approved the study. All patients provided written informed
consent for inclusion in the study.
Data analysis
The values for normally distributed continuous variables, discrete variables, and categorical variables are expressed as the mean ± standard deviation (SD), median (range), and frequency. Comparisons before and after indacaterol therapy were performed using the paired t-test for normally distributed continuous variables, or the nonparametric Wilcoxon rank test for discrete variables. A one-sided P-value of <0.05 was considered statistically significant. Statistical analyses were performed using the Statcel statistical package (Statcel3; OMS Inc, Tokorozawa, Japan).

Results
From February 2013 to May 2014, 23 patients were enrolled. Five patients were excluded from the analyses because of unexpectedly exacerbated comorbid orthopedic disease requiring hospitalization, new malignancy, mild but persistent coarse voice resulting in the patient’s rejection, unavailability during the protocol treatment, and insufficient monitoring data. Thus, 18 patients were evaluable for analyses. The baseline characteristics are shown in Table 1. Among 15 ex-smokers, exposure to excessive smoke was possibly a main cause of COPD in two patients (one man and one woman). None were on active smoking cessation pharmacotherapy. No participants used inhaled corticosteroids.

Despite the increased mean number of steps (3,311.5±2,103.3 to 3,841.8±2,096.8 steps/day, P=0.02), indacaterol did not improve energy expenditure (85.0±77.2 kcal/day changed to 90.9±56.8 kcal/day, P=0.29), exercise duration of light or more exercise (36.4±23.9 minutes/8 hours/day to 40.8±21.6 minutes/8 hours/day, P=0.12), or exercise duration of moderate or more exercise (9.5±15.2 minutes/8 hours/day to 9.2±10.0 minutes/8 hours/day, P=0.55) (Table 2).

Indacaterol significantly improved mean FEV1 (1.46±0.56 L increased to 1.58±0.54 L, P=0.002) and FEV1/VC (55.2±17.9% increased to 61.0±17.3%, P=0.003), CAT scores (16.4±10.2 points at baseline decreased to 12.4±8.2 points, P=0.04). Among eight scales and three component summaries of the SF-36v2, general health scale scores (53.0±19.8 points increased to 63.1±21.3 points, P=0.02), role emotional scale scores (72.5±31.0 points rose to 83.3±24.7 points, P=0.049), and physical component summary scores (41.6±9.7 points at baseline to 45.1±7.9 points at the end of the study, P=0.03), were significantly improved (Table 3).

Discussion
This was the third study, after the studies by Hataji et al16 and Watz et al15 that investigated whether indacaterol improved daily physical activity in patients with COPD. However, the results of our study contradicted those of the previous two studies.

The most important finding is that 12 weeks of indacaterol did not result in a significant improvement in physical activity time in patients with moderate or severe COPD. This result was contrary to those of the previous two studies, which demonstrated that indacaterol significantly improved physical activity in patients with COPD. In a Japanese, non-randomized, and open-label study by Hataji et al Lifeccorder showed a significant increase in physical activity within 4 weeks of the initiation of indacaterol treatment.16 Similarly, in a German, randomized, placebo-controlled, crossover study by Watz et al 3 weeks of indacaterol significantly improved physical activity as measured by the SenseWear Armband®, an exploratory endpoint.15 The discrepancy with our results might be a result of differences in monitoring time and the patient populations. The monitoring times were from the time of awakening to bedtime for 8 consecutive weeks before and after indacaterol introduction in the previous Japanese study,16 for more than 22 hours per day during the last 1 week of a 21-day treatment cycle in the latest German study.13 On the other hand, we monitored for 8 hours in the daytime, 9.00 am - 5.00 pm, and more than 3 non-rainy days before indacaterol introduction and after 12-week treatment. Although indacaterol improved exercise endurance and hyperinflation as early as 3 weeks after treatment,14 this drug also maintained an improvement in pulmonary function and QOL for 12 weeks after treatment.8,11,12 We were also

Table 1 Baseline characteristics of analyzed patients (N=18)

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Baseline data</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>Mean ± SD</td>
</tr>
<tr>
<td>Sex (N)</td>
<td>Male/female</td>
</tr>
<tr>
<td>Body mass index (kg/m²)</td>
<td>Mean ± SD</td>
</tr>
<tr>
<td>Smoking status (N)</td>
<td>CS/ex</td>
</tr>
<tr>
<td>Smoking (packs/year:*</td>
<td>Mean ± SD</td>
</tr>
<tr>
<td>Working status (N)</td>
<td>Worker/retired/housewife</td>
</tr>
<tr>
<td>GOLD stage (N)</td>
<td>I/II/III/IV</td>
</tr>
<tr>
<td>PaO₂ (mmHg)</td>
<td>Mean ± SD</td>
</tr>
<tr>
<td>PaCO₂ (mmHg)</td>
<td>Mean ± SD</td>
</tr>
</tbody>
</table>

Note: *One ex-smoker was excluded because of unknown smoking history.  
Abbreviations: CS, current smoker; ex, ex-smoker; GOLD, Global Initiative for Chronic Obstructive Lung Disease; SD, standard deviation.
Table 2 Changes in daily physical activity (N=18)

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Before indacaterol introduction</th>
<th>After 12-weeks of indacaterol treatment</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Days of analysis (days)</td>
<td>13.3±6.3</td>
<td>19.3±7.6</td>
<td>0.01*</td>
</tr>
<tr>
<td>Number of steps (steps/day)</td>
<td>3,311.5±2,103.3</td>
<td>3,841±2,096.8</td>
<td>0.02*</td>
</tr>
<tr>
<td>Energy expenditure (kilocalories/day)</td>
<td>85.0±77.2</td>
<td>90.9±56.8</td>
<td>0.29*</td>
</tr>
<tr>
<td>Duration of exercise (minutes/day)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Intensity level 1</td>
<td>6.2±6.6</td>
<td>6.6±3.6</td>
<td>0.81*</td>
</tr>
<tr>
<td>Intensity level 2</td>
<td>13.6±7.8</td>
<td>16.5±9.1</td>
<td>0.99*</td>
</tr>
<tr>
<td>Intensity level 3</td>
<td>7.0±5.0</td>
<td>8.4±5.9</td>
<td>0.93*</td>
</tr>
<tr>
<td>Intensity level 4</td>
<td>5.5±7.5</td>
<td>6.1±5.8</td>
<td>0.64*</td>
</tr>
<tr>
<td>Intensity level 5</td>
<td>3.2±6.6</td>
<td>2.1±3.7</td>
<td>0.13*</td>
</tr>
<tr>
<td>Intensity level 6</td>
<td>0.8±1.7</td>
<td>0.9±1.6</td>
<td>0.73*</td>
</tr>
<tr>
<td>≥ intensity level 7</td>
<td>0.1±0.2</td>
<td>0.2±0.2</td>
<td>0.93*</td>
</tr>
<tr>
<td>Duration of light or more exercise (minutes/day)</td>
<td>36.4±23.9</td>
<td>40.8±21.6</td>
<td>0.12*</td>
</tr>
<tr>
<td>Duration of moderate or more exercise (minutes/day)</td>
<td>9.5±15.2</td>
<td>9.2±10.0</td>
<td>0.55*</td>
</tr>
</tbody>
</table>

Notes: *One-sided, paired t-test. Data shown is mean ± standard deviation.

concerned that every day, long-time monitoring might be affected by day-to-day variability such as changes of clothes, bathing, time of awakening and bedtime. As for patient population, patients were of an older (74.2±6.5 years age in our study vs 69.7±4.6 years in the Watz et al study) with a mild stage of %FEV1 < 80%,16 the latest German study recruited only untreated patients with a moderate stage of 50% ≤ FEV1 % <80%,15 while our study recruited untreated patients with moderate or severe stage and included 39% vs 64.02±9.38%,15 respectively), and worse QOL (CAT scores, 16.4±10.2 points in our study vs 11.6±1.5 points in the Hataji et al study). The previous Japanese study included 61% of patients treated with tiotropium and 26% of patients with a mild stage of %FEV1 ≥ 80%,16 the latest German study recruited only untreated patients with a moderate stage of 50% ≤ FEV1 % <80%,15 while our study recruited untreated patients with moderate or severe stage and included 39%

Table 3 Changes in pulmonary functions and QOL questionnaires (N=18)

<table>
<thead>
<tr>
<th>Parameter</th>
<th>N</th>
<th>Before indacaterol introduction</th>
<th>After 12-weeks of indacaterol treatment</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pulmonary functions</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FEV1 (L)</td>
<td>18</td>
<td>1.46±0.56</td>
<td>1.58±0.54</td>
<td>0.002*</td>
</tr>
<tr>
<td>%FEV1 (%)</td>
<td>18</td>
<td>55.2±17.9</td>
<td>61.0±17.3</td>
<td>0.003*</td>
</tr>
<tr>
<td>FVC (L)</td>
<td>18</td>
<td>2.33±0.72</td>
<td>2.49±0.63</td>
<td>0.06*</td>
</tr>
<tr>
<td>mMRC</td>
<td>18</td>
<td>1.3±1.1</td>
<td>1.2±1.0</td>
<td>0.79*</td>
</tr>
<tr>
<td>CAT™</td>
<td>17</td>
<td>16.4±10.2</td>
<td>12.4±8.2</td>
<td>0.04*</td>
</tr>
<tr>
<td>SF-36v2®</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Physical function</td>
<td>17</td>
<td>77.8±16.0</td>
<td>80.6±17.0</td>
<td>0.26*</td>
</tr>
<tr>
<td>Role physical</td>
<td>17</td>
<td>64.3±28.7</td>
<td>74.6±26.5</td>
<td>0.06*</td>
</tr>
<tr>
<td>Body pain</td>
<td>17</td>
<td>74.5±25.4</td>
<td>81.5±23.3</td>
<td>0.06*</td>
</tr>
<tr>
<td>General health</td>
<td>18</td>
<td>53.0±19.8</td>
<td>63.1±21.3</td>
<td>0.02*</td>
</tr>
<tr>
<td>Vitality</td>
<td>17</td>
<td>62.5±25.1</td>
<td>65.4±23.7</td>
<td>0.32*</td>
</tr>
<tr>
<td>Social function</td>
<td>17</td>
<td>74.3±30.8</td>
<td>82.4±28.0</td>
<td>0.15*</td>
</tr>
<tr>
<td>Role emotional</td>
<td>17</td>
<td>72.5±31.0</td>
<td>83.3±24.7</td>
<td>0.049*</td>
</tr>
<tr>
<td>Mental health</td>
<td>17</td>
<td>69.1±25.8</td>
<td>70.9±18.8</td>
<td>0.38*</td>
</tr>
<tr>
<td>Physical component summary</td>
<td>16</td>
<td>41.6±9.7</td>
<td>45.1±7.9</td>
<td>0.03*</td>
</tr>
<tr>
<td>Mental component summary</td>
<td>16</td>
<td>54.7±12.8</td>
<td>54.7±11.2</td>
<td>0.50*</td>
</tr>
<tr>
<td>Role/social component summary</td>
<td>16</td>
<td>41.1±16.6</td>
<td>43.8±15.8</td>
<td>0.19*</td>
</tr>
</tbody>
</table>

Notes: *One-sided, paired t-test; one-sided Wilcoxon signed rank test. Data shown is mean ± standard deviation.

Abbreviations: CAT™, the Japanese version of the chronic obstructive pulmonary disease (COPD) assessment test; FEV1, forced expiratory volume in one second; FVC, forced vital capacity; mMRC, modified Medical Research Council dyspnea scale score; QOL, quality-of-life; SF-36v2®, Medical Outcomes Study 36-Item Short-Form Health Survey, Japanese version 2.
of patients with %FEV$_1$ $<50\%$. Consequently, despite the indirect comparison, our patients might be more inactive even after indacaterol therapy than those in previous studies (total number of steps: 3,841.8$\pm$2,096.8 steps/8 hours/day in our study vs $7,857.7\pm$847.9/waking hours/day in the Hataji et al study$^{16}$ vs $7,341\approx22$ hours/day in the Watz et al study,$^{17}$ and energy expenditure: 90.9$\pm$56.8 kcal/8 hours/day in our study vs 193.6$\pm$23.4 kcal/waking hours/day in the Hataji et al study$^{16}$).

There were several limitations to our study. First, our study was of small sample size, open-label, non-randomized, and non-placebo controlled. Some patients might have been psychologically encouraged to become more active 12 weeks after indacaterol. Second, we did not distinguish between workers and retired patients in analyses of physical activity, because we did not obtain detailed working schedules and activities from the four current workers. Sunday is reported to be different in activity duration from other days, and was the last day entered in the analysis, while retired patients with COPD spend a similar time in physical activities on weekend days compared with weekdays.$^{27}$ Nowadays, irregular working shifts may also make it difficult to monitor the physical activities of workers with COPD.

Based on this study, our next clinical study will evaluate the effect of a LAMA, glycopyrronium, on physical activity in untreated patients with moderate-to-severe COPD (clinical trial number UMIN000014303).

**Conclusion**

In conclusion, we demonstrated that 12 weeks of indacaterol improved respiratory functions and QOL, but did not show an effect on physical activity in patients with moderate-to-severe COPD.

**Disclosure**

The authors report no conflicts of interest in this work.

**References**


